Screener
Indivior Pharmaceuticals, Inc. INDV Total Operating Expenses
Total Operating Expenses at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Indivior Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingExpenses.
The source filing: Indivior Pharmaceuticals, Inc.’s 10-Q, filed April 30, 2026.
- Filed
- Apr 30, 2026, 4:02 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-028850
| Line item | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| Operating expenses: | ||
| Selling, general and administrative | 124 | 133 |
| Research and development | 16 | 22 |
| Total operating expenses | 139 | 156 |
| Operating income | 137 | 66 |
| Other (income) and expenses: | ||
| Interest (income) | (3) | (4) |
| Interest expense | 7 | 12 |
Item 1. Unaudited Condensed Financial Statements.
FAQ
- What is Indivior Pharmaceuticals, Inc.'s total operating expenses?
- Indivior Pharmaceuticals, Inc. (INDV) reported total operating expenses of $139M in Q1 2026.
- How has Indivior Pharmaceuticals, Inc.'s total operating expenses changed year-over-year?
- Indivior Pharmaceuticals, Inc.'s total operating expenses decreased by 10.9% year-over-year, from $156M to $139M.
- What is the long-term trend for Indivior Pharmaceuticals, Inc.'s total operating expenses?
- Over 2 years (2022 to 2024), Indivior Pharmaceuticals, Inc.'s total operating expenses has grown at a 5.5% compound annual growth rate (CAGR), from $827M to $920M.
- What does total operating expenses mean?
- The sum of all operating costs including COGS, SG&A, R&D, D&A, and other operating charges. Revenue minus total operating expenses equals operating income.
Ask your AI about Indivior Pharmaceuticals, Inc.'s total operating expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude